Overall rank by patents
#2,352
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
TANDEM DIABETES CARE, INC.
USPTO PatentsView assignee record — 167 granted patents across 26 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
167
Total patents granted
26
CPC technology areas
18.0
Avg claims per patent
+74%
5-year filing velocity
The verdict
TANDEM holds 167 US patents across 26 technology areas — rank #2,352 of 50,000 tracked assignees.
- #2,352
- of 50,000 US assignees by volume
- Top 9%
- by Innovation Score (53.6/100)
- 18.0
- avg claims per patent
- +74%
- filing velocity, last 5 yrs
Portfolio overview
TANDEM DIABETES CARE, INC. has been granted 167 US utility patents between 2015 and 2025, placing TANDEM DIABETES CARE, INC. at rank #2,352 across all assignees tracked by PlainPatent. This portfolio spans 26 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.0 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, TANDEM DIABETES CARE, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 53.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 106 grants, compared with 61 in the 2015–2019 window — a +74% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. TANDEM DIABETES CARE, INC.'s 18.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 26 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark TANDEM DIABETES CARE, INC. against peers pursuing similar technology classes.
How does TANDEM compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Tandem Diabetes C… ◀ 167
TANDEM DIABETES CARE, INC.
167 patents
What this shows TANDEM holds 167 patents — placing it at rank #2,352 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
TANDEM's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 9% higher than 91% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 9 | 5.4% |
| 2016 | 12 | 7.2% |
| 2017 | 10 | 6.0% |
| 2018 | 11 | 6.6% |
| 2019 | 19 | 11.4% |
| 2020 | 17 | 10.2% |
| 2021 | 15 | 9.0% |
| 2022 | 18 | 10.8% |
| 2023 | 14 | 8.4% |
| 2024 | 22 | 13.2% |
| 2025 | 20 | 12.0% |
Which technologies does TANDEM DIABETES CARE, INC. patent most?
Top 15 of 26 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does TANDEM DIABETES CARE, INC. hold?
TANDEM DIABETES CARE, INC. holds 167 US granted patents filed between 2015 and 2025, spanning 26 technology areas.
What is TANDEM DIABETES CARE, INC.'s Innovation Score?
TANDEM DIABETES CARE, INC. has an Innovation Score of 53.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does TANDEM DIABETES CARE, INC. focus on?
TANDEM DIABETES CARE, INC.'s top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 141 patents. The company has filed patents in 26 CPC subclasses total.
Is TANDEM DIABETES CARE, INC.'s patent filing rate increasing or decreasing?
TANDEM DIABETES CARE, INC.'s recent filing velocity is +74% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for TANDEM DIABETES CARE, INC.'s patents?
TANDEM DIABETES CARE, INC.'s patents average 18.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the TANDEM DIABETES CARE, INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
A61M technology
TANDEM DIABETES CARE, INC.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where TANDEM DIABETES CARE, INC. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
